Published in Eur J Cancer on May 26, 2009
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics (2011) 1.17
A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res (2011) 0.93
Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. BMC Cancer (2012) 0.91
Molecular tests as prognostic factors in breast cancer. Virchows Arch (2014) 0.88
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer (2011) 0.87
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res (2010) 1.92
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Stability of the gross motor function classification system. Dev Med Child Neurol (2006) 1.76
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol (2009) 1.65
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol (2013) 1.62
Bridging the gaps between research, policy and practice in low- and middle-income countries: a survey of researchers. CMAJ (2010) 1.62
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res (2007) 1.51
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol (2013) 1.48
p53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. Eur Arch Otorhinolaryngol (2008) 1.42
Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer (2010) 1.31
Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res (2009) 1.25
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst (2011) 1.23
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res (2006) 1.19
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res (2010) 1.14
Cognitive Ethology and exploring attention in real-world scenes. Brain Res (2006) 1.13
Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer (2011) 1.10
Phased implementation of screening for cryptococcal disease in South Africa. S Afr Med J (2012) 1.05
Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta. J Theor Biol (2004) 1.04
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 1.04
Giant superior mediastinal angioleiomyoma. J Thorac Cardiovasc Surg (2004) 1.03
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica (2005) 1.02
Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat (2008) 1.01
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst (2004) 0.99
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat (2009) 0.93
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 0.93
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Lett (2013) 0.92
Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther (2003) 0.91
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res (2005) 0.89
Aplastic anemia as a late complication of thymoma in remission. Eur J Haematol (2002) 0.88
Reaching further with online education? The development of an effective online program in palliative oncology. J Cancer Educ (2010) 0.88
Thymic function in severely immunodeficient HIV type 1-infected patients receiving stable and effective antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.88
Maximizing clinical benefit with trastuzumab. Semin Oncol (2004) 0.87
Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther (2005) 0.86
The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey. Eur J Health Econ (2011) 0.86
Asynchrony from synchrony: long-range gamma-band neural synchrony accompanies perception of audiovisual speech asynchrony. Exp Brain Res (2007) 0.86
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . Am Soc Clin Oncol Educ Book (2013) 0.85
Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care (2013) 0.85
Simulating simultanagnosia: spatially constricted vision mimics local capture and the global processing deficit. Exp Brain Res (2010) 0.85
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol (2013) 0.84
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 0.84
Cell killing and resistance in pre-operative breast cancer chemotherapy. BMC Cancer (2008) 0.84
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Health Econ (2011) 0.83
Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig (2006) 0.82
Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging (2010) 0.81
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin Cancer Res (2003) 0.81
Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals. Asia Pac J Clin Oncol (2012) 0.79
Using an audit of medical student behavior to inform curriculum change. Teach Learn Med (2010) 0.79
An educational workshop program for rural practitioners to encourage best practice for delivery of systemic adjuvant therapy. J Cancer Educ (2006) 0.79
Postcode prescribing is alive and well in Scotland. BMJ (2002) 0.79
Intraoperative radiotherapy for early breast cancer. Lancet (2010) 0.78
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer (2008) 0.78
Global perception in simultanagnosia is not as simple as a game of connect-the-dots. Vision Res (2009) 0.78
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. PLoS One (2012) 0.78
Practitioner feedback on lung cancer practice guidelines in Ontario. J Thorac Oncol (2006) 0.78
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2011) 0.78
The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. Clin Med (2012) 0.77
Oncology service initiatives and research in regional Australia. Aust J Rural Health (2015) 0.76
Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors. Clin Cancer Res (2008) 0.76
Sweet success. Can Fam Physician (2007) 0.75
Scale-up and continuation of antiretroviral therapy in South African treatment programs, 2005-2009. J Acquir Immune Defic Syndr (2011) 0.75
Diabetes and the proactive laboratory. CMAJ (2006) 0.75
Craniocerebral gunshot injuries. S Afr Med J (2002) 0.75
Differences in health care in South Africa and the UK. Br J Gen Pract (2004) 0.75
A proactive community laboratory and the management of diabetes. Clin Biochem (2005) 0.75
Revised correlation of the Haritalyangar magnetostratigraphy, Indian Siwaliks: implications for the age of the Miocene hominids Indopithecus and Sivapithecus, with a note on a new hominid tooth. J Hum Evol (2005) 0.75
David vs the Goliaths of bossy government. Interview by Victoria Vaughan. Health Serv J (2007) 0.75
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Semin Oncol (2004) 0.75
Recall of lost-to-follow-up pre-antiretroviral therapy patients in the Eastern Cape: effect of mentoring on patient care. S Afr Med J (2012) 0.75
Sternotomy reconstruction with omentum followed by large diaphragmatic hernia. Asian Cardiovasc Thorac Ann (2006) 0.75
A comparison of high-profile and low-profile dynamic mobilization splint designs. J Hand Ther (2004) 0.75
"We will stand by you if you speak out when things are going wrong". Nurs Times (2013) 0.75